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ABSTRACT
Background: Although atrial fibrillation (AF), a common arrhythmia, frequently
presents in patients with underlying valvular disease, its hemodynamic
contributions are not fully understood. The present work aimed to computationally
study how physical conditions imposed by pathologic valvular anatomy act on AF
hemodynamics.
Methods: We simulated AF with different severity grades of left-sided valvular
diseases and compared the cardiovascular effects that they exert during AF,
compared to lone AF. The fluid dynamics model used here has been recently
validated for lone AF and relies on a lumped parameterization of the four heart
chambers, together with the systemic and pulmonary circulation. The AF modelling
involves: (i) irregular, uncorrelated and faster heart rate; (ii) atrial contractility
dysfunction. Three different grades of severity (mild, moderate, severe) were
analyzed for each of the four valvulopathies (AS, aortic stenosis, MS, mitral stenosis,
AR, aortic regurgitation, MR, mitral regurgitation), by varying–through the valve
opening angle–the valve area.
Results: Regurgitation was hemodynamically more relevant than stenosis, as the
latter led to inefficient cardiac flow, while the former introduced more drastic fluid
dynamics variation. Moreover, mitral valvulopathies were more significant than
aortic ones. In case of aortic valve diseases, proper mitral functioning damps out
changes at atrial and pulmonary levels. In the case of mitral valvulopathy, the mitral
valve lost its regulating capability, thus hemodynamic variations almost equally
affected regions upstream and downstream of the valve. In particular, the present
study revealed that both mitral and aortic regurgitation strongly affect
hemodynamics, followed by mitral stenosis, while aortic stenosis has the least impact
among the analyzed valvular diseases.
Discussion: The proposed approach can provide new mechanistic insights as to
which valvular pathologies merit more aggressive treatment of AF. Present findings,
if clinically confirmed, hold the potential to impact AF management (e.g., adoption
of a rhythm control strategy) in specific valvular diseases.
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INTRODUCTION
Atrial fibrillation (AF) is the most prevalent sustained tachyarrhythmia, currently
affecting up to 2% of the general population (Andrade et al., 2014), producing symptoms
(such as chest pain, palpitations, reduced exercise tolerance, shortness of breath) and
decreasing cardiac performance (Fuster et al., 2006). With an estimated number of
33.5 million individuals affected worldwide in 2010, AF has almost reached epidemic
status (Piccini & Daubert, 2014) and is becoming a public health problem in developing
countries (Nguyen, Hilmer & Cumming, 2013). Therapeutic approaches can either pursue
rhythm control–i.e., restoring and maintaining sinus rhythm by antiarrhythmic drugs
or transcatheter ablation–or rate control along–i.e., reducing ventricular rate to reduce
symptoms and improve quality of life (January et al., 2014).
Even though previous clinical data, such as those resulting from the AFFIRM trial
(Wyse et al., 2002), suggested that rate control is not inferior to rhythm control in terms
of survival advantages, this topic is still widely debated and questioned (Al-Khatib et al.,
2014; Ionescu-Ittu et al., 2012). In fact, current literature primarily refers to AF patients
in general, without focusing on the concomitant effect of underlying valvular disease
present in a relevant subgroup of AF patients (Darby & DiMarco, 2012; Vora, 2006).
In addition, hemodynamic measurement data are limited, as AF patients with valvular
diseases are usually excluded from clinical trials so most data are restricted to
echocardiographic measurements (Dahl et al., 2014; Kristensen et al., 2012). Moreover,
interest often focuses on postoperative effects of valve surgery for AF patients (Fukunaga
et al., 2008; Lim et al., 2001).
AF and valvular diseases are often present simultaneously, however their relative
hemodynamic contributions remain unclear (Levy, 2002; Molteni et al., 2014). Although
AF is widely recognized as a risk marker for valve diseases (Gertz et al., 2011; Enriquez-
Sarano & Sundt, 2010; Levy et al., 2015) and is responsible for aggravating valvulopathies
already present (Grigioni et al., 2002; Dujardin et al., 1999; Yamasaki et al., 2006),
in clinical practice it is not easy to understand how physical limitations induced by
valvulopathies act on hemodynamics in AF. In fact, discerning which changes are due to
altered valvular dynamics and which are related to the arrhythmia is rather difficult, and
therefore the overall hemodynamic response in the presence of both pathologies is usually
studied. Moreover, some measurements, such as those based on peak inflow velocity, are
not reliable to study the role of the valvulopathy during AF (O¨zdemir et al., 2001; Thomas,
Foster & Schiller, 1998). From a computational perspective, mathematical modelling offers
new insights into the dynamics of valvular diseases and their effects on the whole
cardiovascular system (Mynard et al., 2012; Broome´ et al., 2013; Domenichini & Pedrizzetti,
2015). However, to the best of our knowledge, the concomitant presence of AF and left
heart valvulopathies has not been analyzed to date.
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A computational approach in this scenario aims to overcome the aforementioned gaps.
The effects of valve pathology and its severity in presence of AF were studied and
compared, from a fluid dynamics point of view, with respect to a reference configuration
where AF is present in the absence of valvular pathology (lone AF). Based on a lumped-
parameter model of the cardiovascular system validated during AF conditions and
characterized by a customizable valve dynamics (Scarsoglio et al., 2014; Anselmino et al.,
2015; Scarsoglio et al., 2016), we simulated hemodynamics in AF with different grades of
left-sided valvular diseases (aortic stenosis, AS; mitral stenosis, MS; aortic regurgitation,
AR; mitral regurgitation, MR) to elucidate the hemodynamic consequences that they
produce during AF. Simulations were carried out over thousands of heart beats, therefore
ensuring the statistical stationarity of the results. Simultaneous hemodynamic parameters
can be derived without approximating, since the complete temporal series of the
cardiovascular variables (pressure, volume, flow rate) were obtained as the primary
output of the model. Moreover, specific severities of valvular pathology can be evaluated,
by mathematically relating the valve opening angle and the valve area, according to the
current guidelines for valve diseases (Baumgartner et al., 2009; Lancellotti et al., 2010a;
Lancellotti et al., 2010b).
This study, concerning a somewhat surprisingly neglected topic, provides new insights
into valvular heart diseases during AF, potentially suggesting which valvular diseases, from
a computational hemodynamic point of view, might require more aggressive AF
management (e.g., a rhythm control strategy such as AF transcatheter ablation). Our
modelling outcomes revealed that both mitral and aortic regurgitation strongly affect
hemodynamics, immediately followed by mitral stenosis, while aortic stenosis has the
least impact among the analyzed valvular diseases.
MATERIALS AND METHODS
Cardiovascular model, variables and parameters definition
The cardiovascular model used here, first proposed by Korakianitis & Shi (2006) for
healthy and diseased valves, has then been validated over more than 30 clinical
measurements regarding AF (Scarsoglio et al., 2014). It has been recently adopted to
evaluate, from a computational point of view, the impact of higher HR during AF at rest
(Anselmino et al., 2015), as well as the role of AF in the fluid dynamics of healthy heart
valves (Scarsoglio et al., 2016).
The model relies on a lumped parameterization of the four heart chambers, together
with the systemic and pulmonary circulation. Cardiac and circulatory regions are
described using electrical terminology, such as compliance (accounting for the elastic
properties), resistance (simulating the viscous effects) and inductance (approximating
inertial terms). The resulting ordinary differential system is expressed in terms of pressure,
P [mmHg], volume, V [ml], flow rate, Q [ml/s], and valve opening angle, # []. Each of
the four heart chambers is active and governed by an equation for mass conservation
(considering the volume variation), a constitutive equation (for the pressure-volume
relation through a time-varying elastance, E), an orifice model equation (relating pressure
and flow rate), and an equation for the valve motion mechanisms. Both systemic and
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pulmonary circuits are partitioned into four arterial and one venous sections. Each
circulatory compartment is ruled by an equation for mass conservation (in terms of
pressure variation), an equation of motion (flow rate variation) and a constitutive linear
equation between pressure and volume. The elastic vessel properties are in general
dependent on the pressure level. However, a linear relation between pressures and
volumes can be assumed in the range of physiological values (Ottesen, Olufsen & Larsen,
2004). The complete system was numerically solved through an adaptive multistep
scheme implemented in Matlab. Since the cardiovascular dynamics present stiff features,
i.e. rapid and abrupt variations in time, a stiff solver implemented in the ode15s Matlab
function was adopted (all the modeling and computational details are given in Scarsoglio
et al. (2014)).
We focused here on the left heart dynamics by means of pressure (P) and volume (V)
variables, also evaluating end-diastolic (ed) and end-systolic (es) values: left atrial pressure
and volume (Pla and Vla, respectively), left ventricle pressure (Plv) and volume (Vlv, Vlved,
Vlves), systemic arterial pressure (Psas, Psas,syst, Psas,dias), pulmonary arterial (Ppas) and
venous (Ppvn) pressures. End-systole is the instant defined by the closure of the aortic
valve, while end-diastole corresponds to the closure of the mitral valve. We introduce
RR [s] as the temporal range between two consecutive heart beats, while HR [bpm] is the
heart rate, i.e., the number of heart beats per minute. Performance indexes are computed
as well:
 stroke volume, SV = Vlved - Vlves [ml];
 ejection fraction, EF = SV/Vlved  100 [%];
 cardiac output, CO = (FVao + RVao)HR [l/min], where FV [ml/beat] and RV [ml/beat]
are the forward and regurgitant volumes, respectively. The forward volume
FV ¼
Z
RR
QþðtÞdt ; (1)
is the volume of blood per beat flowing forward through the valve (the symbol Q+
indicates the positive flow rate outgoing from the valve), while the regurgitant volume
RV ¼
Z
RR
Q tð Þdt ; (2)
is the volume of blood per beat which regurgitates backward through the valve, with the
symbolQ- representing the negative flow rate going backward through the valve (RV < 0
by definition). As FV and RV are here computed for the aortic valve, FVao + RVao is the
net volume per beat [ml/beat] across the aortic valve (Scarsoglio et al., 2016).
Valve dynamics
The valve dynamics introduced by Korakianitis & Shi (2006) include several mechanisms,
such as the pressure difference across the valve, the dynamic motion effect of the blood
acting on the valve leaflet, the frictional effects from neighboring tissue resistance and the
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action of the vortex downstream of the valve. Only the shear stress on the leaflet,
considered negligible, has not been taken into account. The described fluid dynamics,
based on 2D or 3D CFD studies on local flow conditions, was modelled by means of a
lumped parameterization, which leads to a second-order differential equation for each
opening angle, #. Even though the adopted model for the valve motion is lumped, the
equation for the dynamics of the opening angle, #, accounts for different physical
mechanisms. Thus, global variations are modeled and in great part captured through the
temporal variations of the valve area, A, and the opening angle, #. Fine details of the local
dynamics–which are mostly influenced by the shape of the valve area–are not caught,
thereby falling outside the goal of the present work. The angle # reaches values in the
range [#min, #max], where in healthy conditions #min = #min,h = 0
 (closed valve) and #max
= #max,h = 75
 (fully open valve).
We related the valve area, A [cm2], to the opening angle, #, by means of the following
law (Korakianitis & Shi, 2006):
A ¼ ð1 cos#Þ
2
ð1 cos#max;hÞ2
Ah; (3)
where Ah is the reference valve area value for an healthy adult. Only left-sided
valvulopathies were investigated here, thus we set Ah = 5 cm
2 for the mitral valve and
Ah = 4 cm
2 for the aortic valve (Baumgartner et al., 2009; Lancellotti et al., 2010a;
Lancellotti et al., 2010b). In normal conditions, A varies between 0 and Ah, with a
quadratic dependence on #, as reported in Fig. 1 for the mitral (panel A) and aortic
(panel B) valves.
Grading left-sided valve disease severity
For each of the four left valvulopathies (AS, aortic stenosis, MS, mitral stenosis, AR, aortic
regurgitation, MR, mitral regurgitation), we considered three valve area values,
corresponding to different grades of severity (Baumgartner et al., 2009; Lancellotti et al.,
2010a; Lancellotti et al., 2010b):
 AS: As [cm2] = 2 (mild), 1.25 (moderate), 0.90 (severe);
 MS: As [cm2] = 2 (mild), 1.25 (moderate), 0.90 (severe);
 AR: Ar [cm2] = 0.07 (mild), 0.20 (moderate), 0.33 (severe);
 MR: Ar [cm2] = 0.13 (mild), 0.30 (moderate), 0.44 (severe).
Observing the dependence between A and # introduced through Eq. (3), we expect
lower #max values for increasing stenosis severity, and higher #min values for growing
regurgitation grades.
For stenosis conditions, to find the maximum opening angle (#max,s) corresponding to
the stenotic area, As, we exploited Eq. (3) for each grade of severity as follows:
As ¼ ð1 cos#max;sÞ
2
ð1 cos#max;hÞ2
Ah: (4)
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In regurgitant conditions, the minimum opening angle (#min,r) corresponding to the
regurgitant orifice area, Ar, was found reformulating Eq. (3) as reported below:
Ar ¼ ð1 cos#min;rÞ
2
ð1 cos#max;hÞ2
Ah: (5)
From Eqs. (4) and (5) we were able to easily extract the opening angles #max,s and #min,r
related to each grade of stenosis and regurgitation, respectively. A scheme summarizing
the #min and #max values used in the model for the healthy and the twelve valve
diseased configurations is provided in Table S1. Both stenosis and regurgitation were
modelled in a simplified manner through geometrical variations of the opening
angles #, accounting for the mechanical dysfunctions of the valve opening/closure
failure. Because of the lack of clear data, during stenosis the increased stiffness of
the leaflets is neglected, thus these latter were assumed as in healthy conditions.
Altered valvular functions–due to valve prolapse, rheumatic disorders, congenital heart
defects or endocarditis, and usually associated with regurgitation–were also not taken
into account.
The proposed algorithm was used to simulate a specific grade of valvulopathy, once
the corresponding reference valve area value is given. To double check the validity of this
procedure, besides the hemodynamic parameters introduced at the beginning of this
section, we also evaluated as post-processing parameters the regurgitant volumes, RV
[ml/beat] (for regurgitations), and the mean pressure gradients, MPG [mmHg] (for
stenosis), to evaluate the indexes recommended by current clinical guidelines to grade
regurgitation and stenosis severity (Baumgartner et al., 2009; Lancellotti et al., 2010a;
Lancellotti et al., 2010b). Recall that RV for both left valves was calculated as defined in
Eq. (2). ForMPG we used the velocity across the valve, v = Q/A [m/s], and the Bernoulli
equation, defining the transvalvular pressure gradient, P = 4v2 [mmHg]. The mean
pressure gradient, MPG, was calculated by averaging the instantaneous gradients, P,
0 20 40 60θ [°]
0
1
2
3
4
5
A 
[cm
2 ]
severe MS
moderate MS
mild MS
(a)
moderate MR
mild MR
severe MR
0 20 40 60θ [°]
0
1
2
3
4
A 
[cm
2 ]
severe AS
mild AS
moderate AS
(b)
moderate AR
mild AR
severe AR
Figure 1 Valve area A as function of the opening angle #: (A) mitral and (B) aortic valves. Blue curves
represent the healthy behavior, A(#), as expressed by Eq. (3). Black horizontal lines represent As values,
while their intercepts with the blue curve individuate #max,s, for different grades of stenosis, as for-
mulated through Eq. (4). Red horizontal lines reproduce Ar values, while their intercepts with the blue
curve individuate #min,r, for different grades of regurgitation, as expressed through Eq. (5).
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over the systolic phase (i.e., when there is forward flow Q+) (Baumgartner et al., 2009).
Mean pressure gradient, MPG, for stenosis and regurgitant volume, RV (as absolute
values), for regurgitation, are reported in Table S2, as averaged over 5,000 cardiac
periods.
Simulations
To mimic AF conditions, both atria were assumed to be passive, i.e. atrial elastances were
kept constant. A condition of lone AF was first simulated as reference baseline. Then,
twelve simulations reproducing AF together with a specific grade of left valvulopathy were
run. A ventricular contractile dysfunction has been described in both stenosis and
regurgitation (Maganti et al., 2010), though without definitive results (Shikano et al.,
2003). Given the lack of clear data (Scarsoglio et al., 2014) during heart valve diseases in AF,
the reduced left ventricular inotropy was not modelled here and a normal left ventricular
contractility was assumed for all the configurations. For each simulation, the transient
dynamics were exceeded after 20 periods (Scarsoglio et al., 2014). Afterwards, 5,000 cardiac
cycles were computed and recorded to account for a period lasting about one hour. This
choice allowed the statistical stationarity of the results to be achieved. For all the
cardiovascular variables and hemodynamic parameters, mean and standard deviation
values were calculated.
AF beating features were approximated extracting uncorrelated RR from an
Exponentially Gaussian Modified distribution (mean m = 0.67 s, standard deviation  =
0.16 s, rate parameter g = 8.47 Hz), which is unimodal and describes the majority of AF
cases (Hennig et al., 2006; Scarsoglio et al., 2014). The twelve AF with left-valvular disease
simulations present the same AF beating features of the lone AF case. The defective valve
opening/closure was added by varying #max and #min values according to the criteria
discussed in the previous Section.
RESULTS
Outcomes of the thirteen simulations (lone AF simulation, plus twelve AF with left-
valvular disease simulations) are presented in terms of mean, m, and standard deviation,
, values, as computed over 5,000 cardiac periods. The cardiovascular hemodynamic
outcomes for stenosis and regurgitation are given in Tables 1 and 2, respectively. First
columns of Tables 1 and 2 both display reference results of lone AF to facilitate the
comparison. It is worth reading the above Tables also in terms of cv = /m, which gives a
normalized measure of the data dispersion. To better highlight the hemodynamic-based
changes, results are first divided by valvulopathy, with focus on the most severe state.
Representative time series of left atrial and ventricular volumes, together with the
probability density functions of pulmonary vein pressure, Ppvn, and cardiac output (CO),
are shown in Fig. 2 for severe aortic and mitral stenosis (black and red curves,
respectively), and in Fig. 3 for severe aortic and mitral regurgitation (black and red curves,
respectively). Lone AF results are reported in both figures as the baseline configuration
(blue curves). A comparative framework of the diseases accounting for their grading is
then proposed.
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Stenosis
During AS, data dispersion remained practically unvaried with respect to lone AF, with
the only exception of Plv, presenting more dispersion. An increased mean Plv value is a
Table 1 Mean and standard deviation of computed variables during AF with concomitant left-sided valvular stenosis simulations. Lone AF
computed values are also reported.
Lone AF Aortic stenosis (AS) Mitral stenosis (MS)
Mild Moderate Severe Mild Moderate Severe
Pla [mmHg] 9.82 ± 0.82 9.70 ± 0.83 9.69 ± 0.83 9.73 ± 0.83 10.13 ± 0.65 11.07 ± 0.66 12.29 ± 0.71
Plv [mmHg] 47.64 ± 47.35 48.10 ± 48.58 49.71 ± 51.18 51.95 ± 54.67 46.69 ± 47.06 44.45 ± 44.89 41.29 ± 41.74
Vla [ml] 62.80 ± 5.50 62.02 ± 5.56 61.93 ± 5.55 62.17 ± 5.53 64.86 ± 4.31 71.12 ± 4.39 79.24 ± 4.72
Vlv [ml] 93.82 ± 28.39 93.15 ± 27.95 93.99 ± 27.45 95.55 ± 26.78 88.55 ± 26.69 82.41 ± 24.93 76.29 ± 23.20
Vlves [ml] 58.71 ± 2.41 56.26 ± 1.74 56.12 ± 1.88 56.97 ± 2.09 58.11 ± 2.10 55.64 ± 1.81 52.21 ± 1.90
Vlved [ml] 118.28 ± 6.19 116.49 ± 6.78 116.36 ± 6.69 116.99 ± 6.34 117.44 ± 8.86 111.63 ± 11.92 104.12 ± 13.07
Psas [mmHg] 100.39 ± 13.24 101.22 ± 13.13 101.13 ± 12.85 100.58 ± 12.50 99.27 ± 12.97 94.61 ± 12.09 87.91 ± 11.39
Psas,dias [mmHg] 82.56 ± 7.35 83.97 ± 7.94 84.44 ± 7.92 84.34 ± 7.67 81.40 ± 6.80 77.43 ± 5.67 71.82 ± 5.16
Psas,syst [mmHg] 120.94 ± 3.35 121.13 ± 3.52 121.18 ± 3.37 120.55 ± 3.22 119.61 ± 2.58 113.66 ± 2.86 105.56 ± 3.76
Ppas [mmHg] 17.35 ± 4.30 17.30 ± 4.34 17.28 ± 4.33 17.27 ± 4.32 17.57 ± 4.25 18.15 ± 4.03 18.85 ± 3.79
Ppvn [mmHg] 10.36 ± 0.61 10.25 ± 0.62 10.23 ± 0.62 10.26 ± 0.62 10.66 ± 0.58 11.57 ± 0.63 12.76 ± 0.68
SV [ml] 59.57 ± 7.74 60.23 ± 7.86 60.24 ± 7.90 60.02 ± 7.54 59.34 ± 9.65 55.99 ± 11.62 51.91 ± 12.36
EF [%] 50.15 ± 4.35 51.47 ± 4.13 51.54 ± 4.17 51.10 ± 4.00 50.17 ± 4.96 49.59 ± 5.64 49.14 ± 6.01
CO [l/min] 5.60 ± 1.16 5.66 ± 1.24 5.64 ± 1.15 5.61 ± 1.15 5.51 ± 1.20 5.24 ± 1.34 4.83 ± 1.26
Note:
CO, cardiac output; EF, ejection fraction; Pla, left atrium pressure; Plv, left ventricular pressure; Ppas, pulmonary arterial pressure; Ppvn, pulmonary vein pressure;
Psas, systemic arterial pressure; Psas,dias, diastolic systemic arterial pressure; Psas,syst, systolic systemic arterial pressure; SV, stroke volume; Vla, left atrium volume Vlv, left
ventricular volume; Vlved, left ventricular end-diastolic volume; Vlved, left ventricular end-systolic volume.
Table 2 Mean and standard deviation of computed variables during AF with concomitant left-sided valvular regurgitation simulations.
Lone AF computed values are also reported.
Lone AF Aortic regurgitation (AR) Mitral regurgitation (MR)
Mild Moderate Severe Mild Moderate Severe
Pla [mmHg] 9.82 ± 0.82 10.71 ± 0.90 11.99 ± 0.95 12.83 ± 0.93 11.08 ± 1.26 12.37 ± 1.76 13.20 ± 2.09
Plv [mmHg] 47.64 ± 47.35 48.05 ± 46.41 49.03 ± 45.32 49.79 ± 44.79 45.15 ± 43.75 41.77 ± 39.63 38.84 ± 36.52
Vla [ml] 62.80 ± 5.50 68.73 ± 5.99 77.24 ± 6.31 82.86 ± 6.20 71.21 ± 8.43 79.83 ± 11.71 85.34 ± 13.93
Vlv [ml] 93.82 ± 28.39 101.15 ± 34.79 112.25 ± 44.18 120.51 ± 50.65 97.23 ± 36.02 99.67 ± 44.03 100.74 ± 49.28
Vlves [ml] 58.71 ± 2.41 57.90 ± 2.70 57.33 ± 2.46 57.22 ± 2.22 51.45 ± 2.41 42.36 ± 2.43 36.97 ± 1.75
Vlved [ml] 118.28 ± 6.19 133.62 ± 8.04 159.13 ± 11.94 177.95 ± 13.26 130.22 ± 7.69 141.83 ± 9.25 148.96 ± 10.09
Psas [mmHg] 100.39 ± 13.24 93.31 ± 18.04 83.13 ± 25.20 76.15 ± 30.40 91.66 ± 13.07 82.96 ± 12.63 77.54 ± 12.00
Psas,dias [mmHg] 82.56 ± 7.35 69.23 ± 9.95 48.79 ± 12.03 35.09 ± 11.90 74.96 ± 7.38 67.57 ± 7.14 63.16 ± 6.73
Psas,syst [mmHg] 120.94 ± 3.35 119.36 ± 4.19 117.99 ± 3.50 117.79 ± 2.75 112.67 ± 3.22 104.33 ± 3.14 98.71 ± 3.14
Ppas [mmHg] 17.35 ± 4.30 17.69 ± 4.06 18.18 ± 3.66 18.48 ± 3.41 17.94 ± 3.93 18.55 ± 3.56 18.96 ± 3.32
Ppvn [mmHg] 10.36 ± 0.61 11.21 ± 0.64 12.43 ± 0.64 13.23 ± 0.60 11.57 ± 0.88 12.82 ± 1.17 13.61 ± 1.38
SV [ml] 59.57 ± 7.74 75.72 ± 10.04 101.80 ± 13.73 120.73 ± 14.66 78.76 ± 8.98 99.48 ± 10.27 112.00 ± 10.59
EF [%] 50.15 ± 4.35 56.41 ± 4.44 63.68 ± 4.12 67.59 ± 3.56 60.28 ± 3.79 69.95 ± 3.24 75.03 ± 2.47
CO [l/min] 5.60 ± 1.16 5.27 ± 1.50 4.80 ± 2.18 4.45 ± 2.46 5.13 ± 1.26 4.65 ± 1.34 4.34 ± 1.34
Note:
For the abbreviations, please refer to Table 1.
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consequence of the higher aortic resistance during AS and is necessary to guarantee an
adequate CO. Moreover, volume time series (Figs. 2A and 2B) and probability density
functions (Figs. 2C and 2D) preserved the same behavior and shape as observed during
lone AF, thereby confirming the modest hemodynamic impact of AS already evidenced by
data dispersion.
The scenario was different for MS. With respect to lone AF, dispersion of data decreased
for atrial variables (Pla and Vla), Ppvn e Ppas, while performance indexes experienced more
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Figure 2 Aortic and mitral stenosis with AF compared to lone AF. Representative time series (the
same stochastic RR series is used for the three configurations): (A) left atrial volume, Vla; (B) left
ventricular volume, Vlv. Probability density functions: (C) pulmonary vein pressure, Ppvn; (D) cardiac
output, CO. Blue curves: lone AF. Black curves: severe aortic stenosis with AF. Red curves: severe mitral
stenosis with AF.
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dispersion (SV, CO, EF). Atrial overload is detectable by the increased mean Vla and Ppvn
values, as well as by the different shape assumed by the Vla time series and the Ppvn
probability density function with respect to lone AF (Figs. 2A and 2C). Changes at
ventricular level were less pronounced, but largely imputable to inefficient atrial ejection.
This latter in turn reduced Vlved values, leading to an overall SV reduction. The cardiac
efficiency, CO, was weakened as a result of the decreased mean net volume available to be
ejected from ventricle to the aorta.
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Figure 3 Aortic and mitral regurgitation with AF compared to lone AF. Representative time series
(the same stochastic RR series is used for the three configurations): (A) left atrial volume, Vla; (B) left
ventricular volume, Vlv. Probability density functions: (C) pulmonary vein pressure, Ppvn; (D) cardiac
output, CO. Blue curves: lone AF. Black curves: severe aortic regurgitation with AF. Red curves: severe
mitral regurgitation with AF.
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Regurgitation
Both aortic and mitral regurgitation similarly increased the mean atrial volume. However,
MR induced the highest peak values (up to 110 ml) and substantially changed the
temporal dynamics with respect to lone AF (Fig. 3A). The enlarged atrial volume led for
both regurgitations to an increase of Ppvn, with an accentuated right tail for the probability
density function of MR (Fig. 3C).
In case of AR, data dispersion decreased for atrial variables, Ppvn, Ppas, Plv, EF, with
respect to lone AF, while data were sparser for Ppas, CO, Vlv. The failed closure of the aortic
valve during diastole caused substantial regurgitant flow from the aorta back to the
ventricle. This regurgitation on the one hand promoted ventricular overfilling, with
elevated Vlved values (Fig. 3B), which in turn partially inhibited the normal atrial
emptying. On the other hand, the regurgitant flow reduced the net antegrade CO, into the
aorta (Fig. 3D).
Comparing MR with respect to lone AF, data dispersion was lower for Plv, Ppas, SV and
EF, while it increased for atrial variables, Ppvn, Vlv, and CO. The defective closure of the
mitral valve during systole resulted in regurgitant flow from ventricle towards the atrium,
causing high Vla peaks and abnormally emptying of the ventricle after ejection (i.e.,
decrease of Vlves, Fig. 3B). As a consequence, the net forward CO, was reduced (Fig. 3D).
At the end of systole, the atrium was overfilled and ejected a greater amount of blood into
the ventricle during diastole, leading eventually to an increase of Vlved.
Comparative framework of valvular heart disease
Recall that dispersion of data is mainly produced by irregular beating. Changes in the
dispersion of the results–with respect to lone AF–can be interpreted as the (more or less)
pronounced ability of the valvulopathy to modify AF hemodynamics. From this point of
view, AS had the least impact since dispersion remains basically unaltered, while both MR
and AR acted to substantially vary the cardiovascular response.
In order to compare the relative effects of each valvular disease by grade, the percentage
variation of every averaged hemodynamic variable compared to the control, lone AF
simulation, was evaluated. Figure 4 shows the most significant percentage variations,
involving atrial and upstream pulmonary venous return (A), ventricular dynamics
(B and C), performance indexes (D and F), and systemic arterial pressure (E). In the
pulmonary circulation, although mean pulmonary arterial pressure (Ppas) did not
undergo substantial changes, mean pulmonary vein pressure (Ppvn) increased by 31.4,
27.7, and 23.2%, in case of severe MR, AR, and MS, respectively (Fig. 4A). Similarly, mean
left atrial pressure (Pla), increased by 34.4, 30.7 and 25.2% in the cases of severe MR, AR
and MS, respectively. In the left ventricle, an increase in mean left ventricular pressure
(Plv) was seen in severe AS (+9.0%), while there was a decrease in severe MS (-13.3%) and
MR (-18.5%) (Fig. 4B); mean left ventricular volume (Vlv) increased due to severe AR
(+28.8%) and MR (+7.4%), and decreased in case of severe MS (-18.7%) (Fig. 4C).
Concomitantly, stroke volume (SV) showed an upsurge in severe AR (+102.7%) and
MR (+88.0%), and a decrease due to severe MS (-12.9%) (Fig. 4D). Finally, mean
systemic arterial pressure (Psas) declined in severe AR (-24.1%), MR (-22.8%) and
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MS (-12.4%) (Fig. 4E), with an analogous decrease in CO in severe MR (-22.5%),
AR (-20.5%) and MS (-13.8%) simulations (Fig. 4F).
DISCUSSION
The present study focused on computationally assessing the hemodynamic impacts
exerted by different left-sided valve diseases in the context of persistent AF. Previous
literature has not addressed this particular topic, which warrants attention given the
substantial proportion of AF patients presenting with concomitant valvular heart disease.
Indeed, AF frequently complicates mitral valve diseases (MS and MR), especially when
their etiology is rheumatic. In aortic valve diseases, AF has been less well studied, but it
often complicates uncorrected AS or AR (Darby & DiMarco, 2012; Vora, 2006).
To simulate AF in the context of different left-sided valve diseases, we used a lumped
model of the cardiovascular system previously validated for lone AF (Scarsoglio et al.,
2014). This model has two fundamental features: (i) the ability to simulate persistent AF;
Figure 4 Grouped plot displaying percentage variations, referred to lone AF simulation, of selected
computed variables for each concomitant valvular disease. (A) Ppvn, (B) Plv, (C) Vlv, (D) SV, (E) Psas,
(F) CO.
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(ii) a detailed description of valve dynamics, allowing the modelling of different
valvulopathies. In fact, as detailed in the Materials & Methods Section, by developing an
innovative algorithm to model precise severity grades for each valve disease, we were able
to predict hemodynamic variables for each valvular disease, grading the proportional
variation compared to the lone AF simulation. In general, the valvulopathy disease
grading design proved appropriate and reproducible when compared to clinically used
indexes: the calculations of mean pressure gradients across the valve for stenosis and
regurgitant volumes for regurgitation (Table S2) yielded results in agreement with the
ranges indicated by current guidelines (Baumgartner et al., 2009; Lancellotti et al., 2010a;
Lancellotti et al., 2010b). A proper modelling of the ventricular inotropy (here neglected)
is expected to reduce, especially for severe grades of valvular diseases, the systemic and
ventricular pressures as well as the severity indexes (MPG for stenosis and RV for
regurgitation), which are now, therefore, plausibly overestimated. In this setting, though
lacking the presence of autonomic nervous system effects, the model allows one to
simulate the cardiovascular system at a “steady-state” without autonomic influence,
thus highlighting the pure hemodynamic component that each valve disease exhibits
during AF.
During AF, based on the current computational analysis, MR and AR had the strongest
impact on hemodynamics, followed by MS; conversely, AS had by far the least impact
among the studied valvular diseases. In particular, MR displayed the most influence at the
level of the left atrium and in the upstream pulmonary circulation, as indicated by
increased Pla and Ppvn (Fig. 4A), together with a strong impairment in Psas and CO (Figs.
4E and 4F), due to the regurgitating blood volume into the atrium. AR resembled MR
hemodynamically but with more impairment in CO. The MS effects during AF, although
relevant, were less pronounced than either regurgitation, either on left atrium/pulmonary
circulation or on Psas and CO. Finally, in the case of AS, only a small rise in Plv (Fig. 4B)
was seen. For all the other hemodynamic parameters, AS did not show any detectable
trend when shifting from mild to severe grades, while the other valvulopathies clearly did.
From a fluid dynamics point of view, we can try to untangle why regurgitation was
hemodynamically more problematic than stenosis, considering that the latter makes
peak forward flow rate slow and inefficient because of a higher outflow resistance, though
no substantial flow directional variation is introduced with respect to the nonstenotic
state. Changes in flow direction can be quantified by means of the regurgitant volume, RV.
For all grades of both aortic and mitral stenosis, RV absolute mean values did not exceed
6 ml/beat, falling within the physiologic range (Scarsoglio et al., 2016). Regurgitation led
instead to a drastic change in flow direction (please refer to the RV values in Table S2)
which, in the presence of normal valve closure, had no counterpart in healthy dynamics.
As vortex effects play an important role in valve motion (Korakianitis & Shi, 2006),
it can reasonably be expected that their dynamics can be affected when a significant
portion of fluid regurgitates backward.
Moreover, our data demonstrated that mitral valvulopathies are in general more
hemodynamically disruptive than aortic ones for the following reasons. In the case of
aortic valve disease, proper functioning of the mitral valve was able to smooth and damp
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out the upstream changes (at the atrial level and proximally). When instead a mitral
valvulopathy occurred, it directly involved the atrium, a region which already suffered
from contractile dysfunction induced by AF. The mitral valve lost its regulating capability,
thus hemodynamic variations almost equally affected atrial and ventricular regions, also
influencing the upstream pulmonary venous return (e.g., Ppvn) and the downstream
systemic arterial variables (e.g., Psas).
The impact of increasing severity of valvulopathy varied considerably with the lesion.
Mild MS resulted in very little hemodynamic disturbance, only becoming significant with
higher grades of stenosis. In contrast, even milder forms of AR and MR were significant in
the presence of AF. As an example, compared to the control values of lone AF, Ppvn
increased by 11.7% in mild MR and by 31.4% in severe MR (i.e. a nearly three-fold
increase frommild to severe MR), while it underwent an increase of 2.9% in mild MS and
23.2% in severe MS (i.e., an eight-fold increase from mild to severe MS), suggesting that,
although there is adaptation at lower grades, at the severe stage, MS has an impact of
similar magnitude to regurgitation. A likely explanation for this behavior is the absence of
atrial contraction in AF. Often referred to as the “atrial kick,” atrial contraction, when
present, can partially dampen the effects of MS when the grade of the disease is low.
Limitations
In addition to the previously stated lack of autonomic nervous system regulation, some
other limitations of the present modelling study should be considered. First, AF
conditions were set the same for all simulations in the attempt to quantify the “net
impact” of the specific valve disease during the arrhythmia, regardless of other differential
compensatory mechanisms that may, in fact, be present in clinical practice. Second,
coronary circulation was not taken into account, since its peculiar features (e.g., diastolic
flow) makes the modelling challenging; therefore, the effect of AF and different valve
diseases on pressures and volumes in that circulation was not accounted for by the present
model. Third, the model predicted hemodynamic effects of valvular disease during AF,
without considering other pathological conditions, such as hypertension or heart failure,
that could themselves affect cardiovascular variables. Moreover, linear relations are
assumed for the pressure-volume constitutive equations in the vasculature, which can lead
to an underestimation of diastolic pressures in severe stenosis conditions. In the end, AF
beating features were limited to the unimodal distribution only, while multimodal RR
distributions were not analyzed.
CONCLUSIONS
The present study, based on a validated computational cardiovascular model for lone
AF, provides new insights into the consequences of left-sided valvular disease with
concomitant persistent AF, and elucidates which valvular diseases exert the worst
hemodynamic effects. In general, valvular regurgitation had the strongest impact on
hemodynamics, immediately followed by MS. Conversely, AS had the least impact among
the studied valvular diseases. The present findings warrant further clinical investigation
because, if confirmed, they may potentially impact AF management (for example,
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requiring the adoption of more aggressive rhythm control strategies, such as AF
transcatheter ablation) in case of a specific valvular pathology.
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